Depo-Provera Meningioma Lawsuit: Your 2026 Guide

Never Miss a Lawsuit Update

Mark Lawfold as a Preferred Source so you never miss a settlement deadline or new filing.

Thousands of women who received Depo-Provera injections are now filing lawsuits after being diagnosed with meningioma brain tumors. The Depo-Provera meningioma lawsuit has grown into one of the largest pharmaceutical mass torts in the country, with cases consolidated in federal court and the first bellwether trials expected in 2026.

If you used this birth control shot and later developed a brain tumor, you may be entitled to significant compensation. Studies show the risk of meningioma jumps nearly six times higher for women who used Depo-Provera for three or more years.

This is also helpful — James Henry Lawsuit 2026: Full Settlement and Claim Guide

This guide covers everything you need to know right now. You’ll learn who qualifies, what settlements could look like, key deadlines, and exactly how to get your case started before time runs out.

What Is the Depo-Provera Meningioma Lawsuit?

The Depo-Provera meningioma lawsuit is a wave of legal claims against Pfizer alleging the company failed to warn women that its injectable birth control could cause brain tumors. Plaintiffs argue that Pfizer knew about the meningioma risk for years and did nothing to protect patients.

Depo-Provera contains medroxyprogesterone acetate, a synthetic progestin. Women receive an injection every three months to prevent pregnancy. Over 70 million women worldwide have used this drug since its FDA approval in 1992.

Meningiomas are tumors that form in the protective membranes surrounding the brain and spinal cord. While most are classified as benign, they can grow large enough to cause seizures, vision loss, headaches, and neurological damage. Many women have needed brain surgery to remove these tumors.

The core allegation is straightforward. Pfizer sold a product it knew was dangerous without telling women or their doctors about the brain tumor risk. That is a textbook failure-to-warn claim under product liability law.

Depo-Provera Meningioma Lawsuit Update 2026

As of 2026, the Depo-Provera litigation is accelerating. The MDL in the Eastern District of Virginia has grown to include thousands of individual cases, and the court is pushing toward bellwether trials to test how juries respond to the evidence.

Judge Robert Payne has set a schedule for discovery, expert depositions, and case-specific preparation. Plaintiffs’ attorneys have been working through document production from Pfizer, which includes internal communications about what the company knew and when it knew it.

The number of filed cases has surged. By early 2026, estimates put the total case count above 3,000 filed claims in the MDL, with thousands more being prepared by law firms across the country.

Key developments expected in 2026 include:

• Completion of the fact discovery phase
• Expert witness reports and Daubert challenges
• Selection of bellwether cases for trial
• Possible early settlement discussions

The pace of this litigation matters. Mass tort cases often reach settlement discussions after the first bellwether verdicts give both sides a sense of what juries will do. Think of bellwether trials as test drives: they show everyone what the full ride looks like before deciding whether to settle.

Depo-Provera Lawsuit Settlement Amounts

No settlements have been finalized yet in the Depo-Provera litigation as of early 2026. That said, legal experts and plaintiff attorneys have projected potential settlement ranges based on comparable pharmaceutical cases.

Settlement values in individual cases will depend on several factors. The severity of the meningioma, the need for surgery, lasting neurological damage, and the duration of Depo-Provera use all play a role.

These figures are projections based on comparable mass tort settlements. The Zantac litigation, 3M earplug cases, and Roundup settlements provide reference points for how pharmaceutical companies typically resolve mass claims.

The total value of the Depo-Provera litigation could reach into the billions if Pfizer’s internal documents show the company actively concealed the meningioma risk. Cases with strong evidence of corporate concealment tend to produce larger verdicts.

Individual payouts will vary widely. A woman who used Depo-Provera for eight years and needed two brain surgeries will receive far more than someone with a small, monitored tumor.

Key Takeaway: Settlement amounts in the Depo-Provera lawsuit could range from $50,000 to over $1.5 million per case, depending on injury severity and evidence of corporate misconduct.

Who Qualifies for the Depo-Provera Lawsuit?

You may qualify for the Depo-Provera lawsuit if you received Depo-Provera injections and were later diagnosed with a meningioma brain tumor. The connection between the drug use and the diagnosis is the central requirement.

Most attorneys evaluate potential cases using these criteria:

• Received Depo-Provera injections (at least two or more doses)
• Diagnosed with a meningioma (confirmed by MRI, CT scan, or biopsy)
• Timeline connection between Depo-Provera use and tumor development
• Medical records documenting both the drug use and the diagnosis

You do not need to have had brain surgery to qualify. Women whose meningiomas are being monitored through “watchful waiting” may still have valid claims, though surgical cases tend to carry higher value.

Family members of women who died from meningioma complications after Depo-Provera use may file wrongful death claims. These cases have their own eligibility requirements and filing deadlines.

One thing that trips people up: you don’t need to prove with certainty that Depo-Provera caused your tumor. You need to show it’s more likely than not. That is a lower bar than most people expect.

Depo-Provera Brain Tumor Lawsuit

The Depo-Provera brain tumor lawsuit focuses specifically on meningioma, a type of tumor that develops in the meninges. These are the layers of tissue that surround and protect the brain and spinal cord.

Meningiomas account for about 40% of all primary brain tumors diagnosed in the United States. They are the most common type. While doctors label most as “benign,” that word can be misleading. A benign tumor growing inside your skull can still cause serious harm.

Symptoms of meningioma can include:

• Persistent headaches that worsen over time
• Seizures
• Vision problems or double vision
• Hearing loss or ringing in the ears
• Weakness in arms or legs
• Memory and cognitive difficulties
• Personality changes

Many women report that their symptoms were dismissed or misdiagnosed for months or even years before a brain scan revealed the tumor. By that time, some tumors had grown to the size of a golf ball or larger.

The lawsuits allege that Pfizer had enough scientific evidence to add meningioma warnings to the Depo-Provera label but chose not to. If doctors had known about the risk, they could have discussed it with patients before prescribing the drug. That missing conversation is at the heart of every case.

Treatment for meningioma often involves craniotomy surgery, which is the opening of the skull to remove the tumor. Some women need radiation therapy afterward. Recovery can take months, and some women experience permanent cognitive or physical deficits.

How Is Depo-Provera Linked to Meningioma?

The link between Depo-Provera and meningioma comes down to hormones. Meningioma tumors have progesterone receptors on their surface, meaning they can grow in response to progesterone exposure. Depo-Provera delivers a powerful dose of synthetic progesterone every three months.

The science here is not ambiguous. Multiple peer-reviewed studies have established a statistically significant connection.

A landmark 2024 study published in The BMJ (British Medical Journal) followed over 100,000 women and found that prolonged use of injectable medroxyprogesterone acetate increased the risk of meningioma by a factor of 5.6 in women who used the drug for three years or more.

Earlier research from France’s ANSM (National Agency for the Safety of Medicines) prompted French regulators to issue warnings about the connection as early as 2020. France restricted the prescribing of certain progestins after their own data showed elevated meningioma risk.

Think of it this way: meningioma cells have a lock, and progesterone is the key. Flood those cells with synthetic progesterone for years, and you’re essentially fueling potential tumor growth. That biological mechanism is what makes this litigation so scientifically grounded.

Key Takeaway: Multiple studies confirm that Depo-Provera use, especially for three or more years, significantly raises the risk of developing meningioma brain tumors.

Is the Depo-Provera Lawsuit a Class Action?

The Depo-Provera lawsuit is not a class action. It is a mass tort, which works differently. In a mass tort, each plaintiff files an individual case with their own facts, injuries, and potential compensation amount.

Class actions treat all plaintiffs as one group and typically divide a single settlement equally. Mass torts keep cases individual. That distinction matters because your payout reflects your specific injuries, not an average across thousands of claims.

The Depo-Provera cases have been consolidated into MDL No. 3127 (multidistrict litigation) in the Eastern District of Virginia. MDL consolidation puts all federal cases in front of one judge for pretrial proceedings. This speeds up discovery and avoids conflicting rulings.

Each plaintiff retains the right to their own trial if no settlement is reached. After bellwether trials resolve, most mass torts move toward a global settlement framework where cases are valued individually within agreed-upon tiers.

How to File a Depo-Provera Lawsuit

Filing a Depo-Provera lawsuit starts with contacting a law firm that handles pharmaceutical mass tort cases. Most firms offer free case evaluations and work on a contingency fee basis, meaning you pay nothing upfront.

Here is the typical process from start to finish:

Step 1: Free Case Review
You provide basic information about your Depo-Provera use and meningioma diagnosis. An attorney evaluates whether your case meets the filing criteria.

Step 2: Gather Medical Records
Your legal team collects records showing your Depo-Provera prescriptions and your meningioma diagnosis, imaging, and treatment history.

Step 3: File the Complaint
Your attorney drafts and files a formal legal complaint. If filed in federal court, it will be transferred to the MDL in Virginia.

Step 4: Discovery and Litigation
Your case enters the pretrial process. Pfizer must produce documents. Experts are deposed. Bellwether cases are selected.

Step 5: Settlement or Trial
Cases either settle through negotiation or proceed to trial for a jury verdict.

You do not need to travel to Virginia. MDL proceedings handle pretrial matters centrally, but your individual case remains filed through your own attorney.

Depo-Provera Lawsuit Deadline 2026

Filing deadlines for the Depo-Provera lawsuit depend on your state’s statute of limitations for product liability or personal injury claims. Most states give you two to three years from the date you were diagnosed with meningioma or discovered the connection to Depo-Provera.

This “discovery rule” is important. The clock doesn’t necessarily start when you used the drug. It starts when you knew, or should have known, that Depo-Provera may have caused your tumor.

Do not assume you have plenty of time. Statutes of limitations are strict. Miss your deadline by even one day and your case is permanently barred. No exceptions.

If you were diagnosed with meningioma in 2024 or earlier, some state deadlines could expire in 2026 or 2027. Women diagnosed more recently have more time, but the safest approach is to begin the filing process now.

Several states also have “repose” statutes that set an absolute outer deadline regardless of when you discovered the connection. These can cut off claims even if you only recently learned about the Depo-Provera link.

If you're curious, also see Finance Lawsuit April 2026: Settlement and Payout Updates

Key Takeaway: Filing deadlines vary by state and can expire as soon as 2026 for some women, so starting the process now is the safest move.

Depo-Provera Meningioma Settlement Payout

Actual settlement payouts in the Depo-Provera litigation have not yet been distributed as of early 2026. The cases are still in the pretrial and discovery phase. However, understanding how mass tort payouts typically work can give you a realistic picture.

In most pharmaceutical mass torts, the defendant eventually agrees to a global settlement fund. Cases are then sorted into tiers based on injury severity. Each tier has an assigned value range.

Factors that increase your individual payout:

• Longer Depo-Provera use (3+ years shows highest risk and strongest causation)
• Surgical intervention (craniotomy, radiation, or both)
• Permanent neurological damage (cognitive impairment, vision loss, motor deficits)
• Age at diagnosis (younger women with decades of reduced quality of life)
• Lost wages and earning capacity
• Strong medical documentation tying drug use to tumor development

Factors that may lower your payout:

• Short duration of Depo-Provera use (fewer than two injections)
• Small, stable tumors requiring only monitoring
• Incomplete medical records
• Pre-existing conditions that complicate causation

Attorney fees in contingency cases typically range from 33% to 40% of the settlement amount. Litigation costs (expert witnesses, record retrieval, filing fees) are usually deducted separately.

The timeline for payouts will depend on when bellwether trials conclude and whether Pfizer decides to settle. Based on similar mass torts, payouts could begin late 2026 or 2027 if settlement negotiations proceed smoothly after bellwether results.

Depo-Provera MDL 2026

MDL stands for multidistrict litigation, and the Depo-Provera MDL (No. 3127) is housed in the U.S. District Court for the Eastern District of Virginia. Judge Robert Payne oversees all pretrial proceedings for the consolidated federal cases.

The MDL process serves a specific purpose. When thousands of lawsuits raise the same factual questions against the same defendant, consolidating them prevents duplicated work and conflicting court orders. Every plaintiff still has their own case. The MDL just handles shared pretrial tasks in one place.

Here is where things stand in 2026:

• Case count: Over 3,000 individual complaints filed in the MDL
• Discovery status: Pfizer document production ongoing; plaintiff fact sheets being completed
• Expert phase: Experts retained on both sides; Daubert motions anticipated
• Bellwether selection: Candidate cases being identified for trial preparation

The MDL judge has significant power over the pace of litigation. Judge Payne has been active in setting firm deadlines, which is generally a positive sign for plaintiffs who want the case to move forward rather than stall.

New cases continue to flow into the MDL. Women who file federal complaints in any U.S. district court will have their cases transferred to Virginia through a JPML (Judicial Panel on Multidistrict Litigation) order.

Depo-Provera Bellwether Trial 2026

Bellwether trials are test cases selected from the larger pool of MDL plaintiffs. They serve as indicators of how juries might respond to the evidence, the defense arguments, and the damages claims in the full litigation.

In the Depo-Provera MDL, both sides (plaintiffs and Pfizer) have a say in which cases become bellwethers. The court typically selects four to eight cases that represent a range of injuries, usage durations, and demographic profiles.

The first bellwether trials in the Depo-Provera litigation are expected to be scheduled for late 2026 or early 2027. The exact timing depends on how quickly expert discovery wraps up and whether any Daubert challenges (motions to exclude expert testimony) delay proceedings.

What bellwether results mean for your case:

• Plaintiff verdict with large damages: Pressures Pfizer to negotiate a global settlement quickly
• Plaintiff verdict with modest damages: Still pushes toward settlement, but at lower values
• Defense verdict: Slows settlement talks; Pfizer gains negotiating leverage
• Mixed results: Both sides reassess; settlement negotiations become more complex

Think of bellwether trials like the opening act at a concert. They set the tone for everything that follows. A strong plaintiff win in the first bellwether can accelerate the entire settlement timeline by months or even years.

Pfizer’s defense strategy will likely focus on arguing that meningiomas have other causes (hormonal factors, genetics, prior radiation exposure) and that the company’s warning label was adequate.

Key Takeaway: Bellwether trials expected in late 2026 or early 2027 will be the single most important factor in determining settlement amounts and timelines for all Depo-Provera cases.

Depo-Provera Side Effects and Meningioma

Depo-Provera’s FDA-approved label lists numerous side effects, but for years it did not include meningioma. The lawsuit centers on this missing warning. Known and listed side effects of Depo-Provera include:

• Irregular menstrual bleeding or amenorrhea
• Weight gain (average 5 to 10 pounds in the first year)
• Bone density loss with prolonged use
• Headaches
• Mood changes, including depression
• Decreased libido
• Injection site reactions

The bone density warning was added to the label in 2004 after studies showed long-term use could weaken bones. Plaintiffs argue that if Pfizer could update the label for bone loss, it could have updated it for meningioma risk too.

What sets meningioma apart from other side effects is the severity and permanence. You can regain bone density after stopping Depo-Provera. You cannot simply “undo” a brain tumor that required surgery.

The FDA received hundreds of adverse event reports linking Depo-Provera to meningioma through its FAERS (FDA Adverse Event Reporting System) database. Despite these reports and mounting international evidence, no meningioma warning was added to the U.S. label.

This gap in the labeling is what gives plaintiffs their strongest argument. The science was there. The reports were there. The warning was not.

Depo-Provera Meningioma Risk Studies

The scientific evidence connecting Depo-Provera to meningioma is substantial and growing. Several major studies have been published in peer-reviewed journals, and their findings are central to the lawsuit.

BMJ Study (2024)
Published in The BMJ (British Medical Journal), this large-scale study analyzed data from over 100,000 women. It found a 5.6-fold increased risk of intracranial meningioma among women who used injectable medroxyprogesterone acetate for three or more years. Even shorter durations showed elevated risk, though at lower magnitudes.

French National Study (2021)
Researchers working with France’s national health insurance data found a strong association between prolonged progestin use and meningioma. This study was influential in prompting French regulators to restrict certain progestin-based medications.

Earlier Case Reports and Smaller Studies
Individual case reports and smaller studies dating back to the early 2000s had flagged the meningioma-progestin connection. These studies showed that meningioma tissue frequently expresses progesterone receptors, providing the biological mechanism for tumor growth.

What makes this litigation different from some pharmaceutical lawsuits is the strength of the science. The biological mechanism (progesterone receptors on meningioma cells) is well understood. The epidemiological data (large population studies) is robust. The dose-response relationship (higher risk with longer use) is clear.

Pfizer will likely argue that correlation does not prove causation at the individual level. But the weight of evidence across multiple study types and countries makes that argument difficult to sustain in front of a jury.

Key Takeaway: Peer-reviewed studies, especially the 2024 BMJ study showing a 5.6x risk increase, provide strong scientific support for the claim that Depo-Provera causes meningioma.

Depo-Provera Lawsuit Eligibility

Eligibility for the Depo-Provera lawsuit depends on three core factors: whether you used the drug, whether you were diagnosed with meningioma, and whether you can connect the two through medical records.

You likely qualify if:

A related guide: Depo-Provera Lawsuit Lawyers: Your 2026 Full Guide

• You received at least two Depo-Provera injections (covering a minimum of six months)
• You have a confirmed meningioma diagnosis from imaging (MRI or CT) or pathology (biopsy/surgical specimen)
• Your diagnosis occurred during or after your period of Depo-Provera use
• You are within your state’s statute of limitations

You may still qualify even if:

• Your meningioma was classified as “benign”
• You did not require surgery (watchful waiting cases may still have claims)
• You used Depo-Provera many years ago
• You also used other hormonal contraceptives

You likely do not qualify if:

• You never received Depo-Provera injections
• You were diagnosed with a different type of brain tumor (glioma, schwannoma, etc.)
• Your statute of limitations has expired

Attorneys typically ask for your pharmacy records, medical charts, imaging reports, and surgical notes during the evaluation process. If your pharmacy records are no longer available, your doctor’s clinical notes showing Depo-Provera prescriptions can serve as proof.

Women who used Depo-SubQ Provera 104 (a subcutaneous version of the same drug) are also eligible. The active ingredient is identical.

For more context, see Live Olympics Lawsuit 2026: Settlement and Filing Update

Pfizer and the Depo-Provera Lawsuit

Pfizer is the defendant in the Depo-Provera meningioma litigation. The company acquired the drug through its 2003 acquisition of Pharmacia, which had originally developed and marketed Depo-Provera through its subsidiary Pharmacia & Upjohn Company.

Pfizer has generated billions of dollars in revenue from Depo-Provera sales over the past two decades. The drug remains on the market and continues to be prescribed in the United States and globally.

The central allegation against Pfizer is failure to warn. Plaintiffs claim the company:

• Had access to scientific data showing the meningioma risk
• Received adverse event reports through the FDA’s reporting system
• Watched as international regulators in France and elsewhere took action
• Still chose not to update the Depo-Provera warning label for U.S. patients

Pfizer’s defense is expected to center on several arguments:

• Meningiomas are relatively common and have many potential causes
• The company’s label was adequate and met FDA requirements
• Individual plaintiffs cannot prove their specific tumor was caused by Depo-Provera
• The science was evolving and did not warrant a label change at the time

Pfizer has a track record of settling pharmaceutical litigation. The company resolved thousands of Zoloft birth defect claims and Protonix injury claims in prior mass torts. That history suggests a settlement path is possible once bellwether trials clarify the strength of the plaintiff case.

Depo-Provera Lawsuit Filing Process

The filing process for the Depo-Provera lawsuit is designed to be straightforward for plaintiffs. Most of the heavy lifting is handled by your legal team. Here is a more detailed breakdown of each stage.

Initial Consultation
During your first call with an attorney, you’ll answer questions about how long you used Depo-Provera, when you were diagnosed with meningioma, what treatment you received, and how the tumor has affected your daily life. This call usually takes 15 to 30 minutes.

Document Collection
Your attorney’s team will request medical records, pharmacy records, and imaging reports. You’ll sign HIPAA authorization forms so they can obtain these directly from your healthcare providers. This phase can take several weeks depending on how quickly your providers respond.

Case Filing
Once your attorney has enough documentation, they file a formal complaint in federal court. The JPML then transfers the case to the MDL in Virginia.

Plaintiff Fact Sheet
After your case enters the MDL, you’ll be required to complete a Plaintiff Fact Sheet (PFS). This standardized document asks for detailed information about your medical history, drug use, and injuries. It replaces the need for initial depositions in most cases.

Ongoing Litigation
From here, your case moves through the MDL process alongside thousands of others. You may be asked to provide a deposition, but most plaintiffs have minimal involvement beyond the initial setup.

Key Takeaway: Filing a Depo-Provera lawsuit requires minimal effort from you; your attorney handles records, filings, and litigation while you focus on your health.

Frequently Asked Questions

Can I still file a Depo-Provera meningioma lawsuit in 2026?

Yes, most women can still file in 2026.

Your deadline depends on your state’s statute of limitations, typically two to three years from your diagnosis or discovery of the Depo-Provera connection.

Contact an attorney now to confirm your specific deadline before it passes.

How much money can I get from the Depo-Provera settlement?

Projected settlement amounts range from $50,000 to over $1.5 million per case.

Your specific payout depends on the severity of your meningioma, whether you needed surgery, and how long you used Depo-Provera.

No settlements have been finalized yet, but payouts could begin in late 2026 or 2027.

How long do you have to use Depo-Provera to get meningioma?

Studies show the risk increases significantly after one year of use and jumps to 5.6 times higher after three or more years.

Even shorter durations may carry some elevated risk.

Women who received at least two injections may qualify for the lawsuit.

Is the Depo-Provera lawsuit a class action or mass tort?

The Depo-Provera lawsuit is a mass tort, not a class action.

Each plaintiff files an individual case and receives compensation based on their own injuries and circumstances.

Cases are consolidated in MDL 3127 for pretrial efficiency, but each case is valued separately.

When will Depo-Provera lawsuit payouts begin?

Payouts are expected to begin in late 2026 or 2027, depending on bellwether trial outcomes and settlement negotiations.

Mass tort payouts typically start after the first trial verdicts establish the value of claims.

The exact timing will depend on how quickly Pfizer agrees to a settlement framework.

Take Action on Your Depo-Provera Claim Now

The Depo-Provera meningioma lawsuit is moving fast. Bellwether trials are on the horizon, and filing deadlines are approaching for women diagnosed in 2023 and 2024.

If you used Depo-Provera and developed a brain tumor, now is the time to get your case evaluated. Gather your medical records, pharmacy records, and imaging reports.

Start the process today. The window to file won’t stay open forever, and early filers are often in the strongest position when settlements are distributed

Also worth exploring: Truvada Lawsuit Settlement: What to Expect in 2026

Also worth exploring: Harvard Tylenol Lawsuit: 2026 Case Updates, Payouts

Also worth exploring: Shocking Entertainment Lawsuit 2026: Claims and Payouts

Never Miss a Lawsuit Update

Mark Lawfold as a Preferred Source so you never miss a settlement deadline or new filing.